Clinical Trial Update: Tezspire Cardiac Events PASS

View source ↗

Summary

A post-authorization safety study (PASS) evaluating cardiovascular events, including major adverse cardiovascular events (MACE), in Tezspire-treated patients is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Tezspire (tezepelumab)

Snippet

Sponsor: AstraZeneca | Conditions: Cardiovascular Events, MACE | Status: RECRUITING